fda update on semaglutide What's New in Obesity Treatment? FDA alerts health care providers,

Mild hypoglycemia (self-treatable episodes) occurred at similar rates to placebo in several trials, and often decreased as patients lost weight and improved insulin sensitivity over time

One in 8 American adults now takes a GLP-1 drug of some kind

We evaluate metabolic function through lab work and build treatment strategies around how your body actually responds instead of guessing what should work

Nie twierdz, e GLP-1 nie dziaa

Endocrinology 139 , 40044007 (1998)

For some infertility phenotypes associated strongly with metabolic dysfunction, such as PCOS with obesity and insulin resistance, GLP-1 RAs could be contemplated prior to or concurrently with standard ovulation agents like clomiphene or letrozole